Autism Stem Cell Therapy FAQ for Parents

No. We describe autism regenerative medicine as a supportive, individualized program rather than a cure. Mesenchymal stem cells (MSCs) may support neuroinflammatory modulation, immune regulation, and neurotrophic signaling — but outcomes are highly individual. Our team is transparent about realistic expectations during every consultation.

Because emerging research suggests that subgroups of children on the autism spectrum show elevated neuroinflammation, immune dysregulation, and altered gut-brain signaling. MSC therapy is explored for its ability to modulate these pathways through paracrine factors such as IL-10, TGF-β, and BDNF — not as a behavioural intervention, but as a biological support strategy.

We use a consultation-first pathway: families submit medical records, receive a candidacy review, and only then proceed to travel planning. Our international coordination team arranges airport transfers, hotel accommodation near the clinic, treatment scheduling, and companion logistics so families can focus on their child.

Developmental history, formal autism diagnosis reports, prior therapy records (ABA, speech, OT), current medications, relevant lab work (immune panels, GI assessments), and any recent specialist notes. More complete records allow our medical team to design a more individualized protocol.

Our protocols use Wharton's Jelly–derived mesenchymal stem cells (WJ-MSCs) from ethically donated umbilical cord tissue. These allogeneic cells are young, immunologically privileged (no HLA matching required), and demonstrate strong anti-inflammatory and neurotrophic properties. All cell processing occurs under GMP-aligned quality controls.

We evaluate children from age 2 and above. Earlier intervention may benefit from greater neuroplasticity during critical developmental windows. However, older children and adults on the spectrum are also evaluated based on their individual profile, medical history, and treatment goals.

Depending on the protocol, administration may include IV (intravenous) infusion for systemic immune modulation, intrathecal injection for direct CNS delivery, and/or intranasal exosome delivery. The combination is determined during medical consultation based on age, weight, and clinical profile.

Based on clinical experience and published research, families have reported improvements in speech and language, social engagement, eye contact, behavioural regulation, sensory processing, sleep quality, and gastrointestinal function. Individual outcomes vary significantly and are not guaranteed.

Most autism treatment visits require 5–10 days in Istanbul, depending on the specific protocol, number of sessions, and whether additional assessments are included. We help families plan a comfortable stay with clear scheduling from day one.

MSC therapy has been studied in thousands of pediatric applications globally with an excellent safety profile. Wharton's Jelly MSCs are immunologically privileged, virtually eliminating rejection risk. Common temporary effects include mild fatigue or low-grade fever lasting 24–48 hours. No serious adverse events have been reported in pediatric MSC literature.

Absolutely. We encourage families to continue all existing therapies. Regenerative medicine is designed to complement — not replace — behavioral, developmental, and educational support. Many families report that gains from ongoing therapies seem to accelerate after treatment.

Treatment costs in Istanbul are typically 40–60% lower than equivalent programs in the US, UK, or Europe. Exact pricing depends on protocol complexity, number of infusions, and whether exosome therapy is included. Contact our team for a detailed estimate after medical record review.